News
-
-
PRESS RELEASE
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces a registered direct offering of common shares and warrants to a fundamental institutional investor for gross proceeds of approximately US$2 million. D. Boral Capital LLC acts as the exclusive placement agent for the Offering -
-
-
-
PRESS RELEASE
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
NanoViricides, Inc. highlights the need for a revolutionary antiviral drug like NV-387 as response to Andes hantavirus incident on a cruise ship, emphasizing potential global epidemic risk -
-
-
-
PRESS RELEASE
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
NanoViricides, Inc. comments on their drug candidate NV-387 as a weapon against measles outbreaks worldwide. The drug shows promise in treating patients and preventing transmission
